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1. Introduction 
1.1 Capsaicin sensitive nerve endings, their functions and the neurogenic 
inflammation 
The capsaicin sensitive nerve endings have three roles: afferent, local and systemic efferent 
functions. The classic afferent function means that the sensory nerve ending sends signals into 
central nervous system evoked by a stimulus (capsaicin, heat, mechanical stimulus, pH change, 
etc.) and nociception arises; the pain is the subjective perception of it. Beside this, different 
neurotransmitters are also released from the activated nerve ending, which exert local and 
systemic effects. Vasodilation, plasma protein extravasation, inflammatory cell activation, 
edema (neurogenic inflammation) are caused. Such neurotransmitters are the substance P 
(SP), neurokinin A (NKA), neurokinin B (NKB) which belong to the tachykinin family. This can 
be considered the local efferent function of the capsaicin sensitive nerve endings. 
Somatostatin is also released from the activated sensory nerve endings into the circulation, 
which has an antiinflammatory and analgesic effect (Pintér & Szolcsányi 1996; Szolcsányi, 
Helyes, et al. 1998; Szolcsányi, Pintér, et al. 1998). This is the systemic efferent function of 
sensory nerve endings. 
1.2 Transient Receptor Potential Vanilloid 1 (TRPV1) receptor 
The Transient Receptor Potential Vanilloid 1 receptor is a nonselective cation channel 
activated by painful thermal stimulus (above 43 °C), acidic pH (Tominaga et al. 1998), 
numerous exogenic compound (capsaicin, resiniferatoxin, piperin, zingeron, gingerol, etanol) 
(Szolcsányi 1983; Szallasi & Blumberg 1989; Patacchini et al. 1990; Szallasi & Blumberg 1990; 
Caterina et al. 1997; Liu et al. 2000; Dedov et al. 2002) as well as endogenous substances 
(anandamide, lipoxygenenase products, N-oleoil-dopamine) (Hwang et al. 2000; Trevisani et 
al. 2002; Chu et al. 2003). TRPV1 receptor has been being successfully cloned  about one and 
half decades ago (Caterina et al. 1997; Caterina & Julius 2001; Clapham et al. 2003). The 
channel is built up from six transmembrane domains; the fifth and sixth domain is connected 
by a short hidrophobic flexible chain which takes part in the pore formation. The receptor is 
active in tetrameric form (Clapham et al. 2003).  
Upon its activation, many different signal transduction pathways are activated or inactivated, 
the most important outcome is the cell membrane depolarization caused by calcium influx. 
The calcium accumulation can cause the elevation of cGMP level in a specific manner (Wood 
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et al. 1988). The phosphorilation sites of PKC (Bhave et al. 2003; Dai et al. 2004; Premkumar 
et al. 2004), PKA (De Petrocellis et al. 2001; Rathee et al. 2002; Bhave et al. 2003), and 
Ca2+/calmodulin dependent protein kinase II (CaMKII) enzymes on the TRPV1 receptors (Wood 
et al. 1988) are found. 
TRPV1 receptors have an important role in the transmission of painful stimuli (nociception) 
and their presence is also discovered in the central nervous system where they have a role in 
the integration of painful stimuli (Huang et al. 2002; Cui et al. 2006). The activation of TRPV1 
receptors causes the release of tachykinins from the sensory nerve endings and they are 
functioning as one of the important regulator of tachykinin system, too. 
1.3 Tachykinin system 
The first member of the tachykinin family was discovered by von Euler and Gaddum. In the 
’80, the mammalian tachykinin family was expanded with new members such as substance K 
(neurokinin A, NKA according to the new nomenclature) and neuromedin K (now it is called 
neurokinin B, NKB), neuropeptide K and neuropeptide γ which are the variants of NKA (Kimura 
S. 1983; Nawa et al. 1984; Tatemoto et al. 1985; Kage et al. 1988). 
The receptors were discovered and characterized along with the mediators (Masu et al. 1987; 
Yokota et al. 1989; Biolow et al. 1990). Tachykinins are released mostly from the capsaicin 
sensitive nerve endings but they can be detected in other tissues beside neuronal structures. 
Tachykinin receptors are G-protein coupled receptors. Three receptors are known until now 
(neurokinin 1, 2, 3), their affinity and specificity are different to the given tachykinins. 
The tachykinins are involved in several physiological processes. The tachykinins released in the 
spinal dorsal root area are involved in nociception. They also influence the colinergic and 
adrenergic signal transduction (Grant 2002), but their most prominent effect is the mediation 
of neurogenic inflammation. Neurogenic inflammation is characterized by local vasodilation, 
plasma extravasation, edema formation and accumulation of inflammatory cells. The 
tachykinins can evoke smooth muscle cell contraction by the direct or indirect degranulation 
of mast cells causing histamin release (Jancsó et al. 1967; Jancsó et al. 1968; Szolcsányi 1984; 
Szolcsányi 1996a; Barthó et al. 2004). 
Substance P binds to NK1 receptor, the NKA to NK2 receptor while NKB to NK3 receptor 
preferentially; they act as full agonist on the preferred receptor. SP causes the increase of the 
permeability of the vessels, plasma protein extravasation, enhances the production of 
inflammatory cytokines and the chemotaxis of T cells. With this effect they facilitate the 
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accumulation of neutrophil granulocytes, degranulation of mast cells and proliferation of 
lymphocytes (Grant 2002). SP increases the secretion of salivary glands, gastrointestinal tract 
and pancreas (Lembeck & Starke 1968; Konturek et al. 1981). Furthermore, they foster the 
proliferation and wandering of endothelial cells and the  formation of new vessels (Maggi 
1995). NKA shows the biggest affinity toward NK2 receptors; causes plasma extravasation, 
smooth muscle contraction and stimulates inflammatory cells (De Swert & Joos 2006) like SP. 
NK2 receptors act mainly on the perifery but they can be found in central nervous system, too. 
The NK3 receptor which can be found mainly in central nervous system, binds NKB, can be 
detected on the perifery as well (Frossard & Advenier 1991), but their role in neurogenic 
inflammatory processes seems less prominent. 
After 2000 the tachykinin family was expanded with the freshly discovered hemokinins 
encoded by the Tac4 gene (Zhang et al. 2000). Several products of this gene are synthetized 
in human with alternative splicing which are called endokinins (EKA, B, C, D) and hemokinins 
(HK). There is only one variant in mice and rats called hemokinin-1 (HK-1). These new members 
with the suggested receptor conformers and tissue-specific post-translational modifications 
build up a fine-tuned tachykinin system where many cell lines and signal transduction 
pathways are involved (Page 2004; Page 2005). 
1.4 The role of neurogenic inflammation in the airways. 
Airway inflammation can be studied in different animal models. The most used are the 
endotoxin (LPS) evoked airway inflammation (Helyes & Hajna 2012), or the cigarette smoke 
induced chronic obstructive pulmonary disase (COPD) model (Shapiro 2000). The LPS-induced 
inflammation is a neutrophil granulocyte dominated acute inflammation while the smoke 
exposure leads to  chronic changes, causes emphysema and fibrosis (Churg et al. 2008). 
Inflammatory and immune cells are also capable to produce tachykinins upon certain 
inflammatory stimuli. The cellular tachykinins have important role in airway inflammation 
such as asthma and COPD (Groneberg et al. 2006). Pulmonary epithelial cells can express SP 
in viral infection (Stewart et al. 2008). 
The preferred ligands for NK1 and NK2 receptors are SP and NKA respectively (Frossard & 
Advenier 1991; Regoli et al. 1994). Our research group confirmed previously that in acute lung 
inflammation the simultan activation of NK1 and NK2 receptors play role in the neutrophil 
accumulation and the NK2 receptors are responsible for the increased airway resistance 
(Elekes et al. 2007). 
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 Since the discovery of the third preprotachykinin gene (Tac4), the number of tachykinins is 
doubled, numerous peptides had been identified in the peripheral organs in many species and 
broad spectrum effects had been described (Page 2004; Page 2005; Page 2006). Hemokinins 
and endokinins show significant selectivity and potency on NK1 receptors and may take part 
in inflammatory cell functions (Groneberg et al. 2006; Page 2006). SP-like endokinins which 
are expressed mainly peripherally are thought to be NK1 receptor agonists (Page 2004), but 
the tachykinin system seems to be much more complex than it was thought at the beginning. 
Several tachykinin-mediated processes show tissue specificity which make possible the unique 
interactive combination of the tachykinins and receptor configurations (Page 2006).  
1.5 A neurogén gyulladás jelentősége a vastagbélben 
Neurogenic inflammation and neuroimmune interactions have proved to take part in the 
development of IBD. It is important to study the involvement of sensory nervous system. Few 
authors have described afferent nerve fibers expressing TRPV1 receptors among the extrinsic 
sensory neurons in rodents (Patterson et al. 2003; Ward et al. 2003), while others have found 
TRPV1-like immunoreactivity on intrinsic enteral neurons in guinea pigs, domestic pigs and 
human (Poonyachoti et al. 2002; Anavi-Goffer & Coutts 2003; Chan et al. 2003). Under 
physiological circumstances, the TRPV1-expressing afferent neurons play important role in the 
regulation of gastrointestinal circulation, secretion, mucosal homeostasis, motility and 
nociception (Holzer & Barthó 1996; Holzer & Maggi 1998). 
The adequate pharmacological treatment of inflammatory bowel diseases is still a major 
problem nowadays. Treatments come with several unwanted sideeffects. As a result of latest 
developments, specific antibodies against proinflammatory mediators had been introduced 
into therapy (anti-TNF-α antibody, infliximab), but the underlying pro- and antiinflammatory 
regulatory mechanisms are still not fully elucidated. 
The most likely cause of inflammatory bowel disease is the damage of the interepithelial tight 
junctions and the reaction triggered by the invading luminal antigens. One important 
component of this process is the activation of the sensory nerve endings and neurogenic 
inflammation (Yamamoto et al. 1996; Gross & Pothoulakis 2007). There is a novel finding that 
the SP released from TRPV1 expressing neurons is an aggravating factor in ulcerative colitis 
(Engel et al. 2012). 
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1.6 Necessity of the development of new drugs 
Currently the adequate therapy of inflammatory disease is not resolved as specific inhibitor of 
the neurogenic component of inflammation is not available. One of this significant health 
problem is the group of inflammatory bowel diseases and the airway inflammations. The role 
of neurogenic component has been proved to be relevant in the development of 
inflammation. I focused on the inflammation of bowels and airways as both are big organ 
systems, direct connection with the external environment, their inflammation is affecting 
numerous people. 
As the exact patomechanism is not fully uncovered (and probably we are facing with 
multifactorial disease), causal therapy cannot be performed, the aim is the control of the 
disease and deceleration of its runoff (Gaál 2012). 
There are several high efficiency antiinflammatory agents in the treatment of bowel 
inflammations (corticosteroids, TNF-α inhibitors), but they can cause severe sideeffects 
especially during chronic administration. Currently, the substances be classified in three main 
groups: local corticosteroids, systemic immunsuppressants (methotrexate, cyclophosphamide 
and azathioprine) and the newest monoclonal antibodies (infliximab, etanercept, 
adalimumab, certolizumab, natalizumab). 
Similar approach is used in the treatment of airway inflammations. The therapy of chronic 
airway inflammatiory diseases (asthma bronchiale) is based on locally administered 
corticosteroids (budesonid, fluticason, mometason), and the systemic administered 
leukotriene antagonists (montelukast, zafirlukast, pranlukast). These drugs should be 
administered continuously to prevent the development of chronic inflammation which can 
lead to acute exacerbations. In severe cases, biologic therapy is used (omalizumab in the 
corticosteroid resistant allergic asthma).  
Opportunistic infections (fungal, bacterial and viral infection) may arise as a consequence of 
local ol systemic immunesuppression or endocrine changes can occur due to the disturbance 
of hormonal balance. Also, the newest biologic treatments are not free from sideeffects; 
exacerbation of severe, latent infections (tuberculosis) or development of multiple sclerosis, 
progressive multifocal leukoencephalopathy (PML) were observed (Mir Subías et al. 2013; 
Piusińska-Macoch 2013).  Furthermore, the biologic therapy is expensive. 
The chronic inflammation may cause irreversible damage in the lung, the permanent tissue 
remodeling (emphysema, fibrosis) interferes with the pulmonary functions and lowers the 
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quality of life of the patient. Obviously, surgical intervention is not available which could 
improve the condition of the patient.  
All of these justify to make efforts to develop anti-inflammatory agents with new mechanism 
by clarifying the regulatory mechanisms of inflammation. One of the possible method could 
be the use of selective receptor antagonism to intervent the development of inflammation. 
2. Aims 
Airway inflammation model: 
a) Investigating the role of the neurokinin 1 receptor in the LPS-induced airway 
inflammation. 
b) Explore the role of certain transmitters (SP, NKA) and their receptor (NK1) in the 
endotoxin-induced airway inflammation, analyzing the effects of mediators and their 
receptors to the different components of inflammatory processes.  
c) Observe the inflammatory processes and their consequences (airway hyperreactivity) 
caused by chronic cigarette smoke exposure in Trpv1 KO and Tac1 KO, NK1 KO mice. 
Bowel inflammation model:  
a) Analyze the role of the TRPV1 receptors in dextran-sulfate induced colitis ulcerosa in 
animal model with two DSS concentrations. 
b) Investigate the expression of NK1 receptors and different tachykinin genes in intact and 
colitic animals.  
c) Discover the effect of NK1 receptor antagonism in DSS-induced colitis on local cytokine 
production. 
3. Experimental models and methods 
3.1 Airway inflammation models 
3.1.1 Animals 
All of the animals used in this experiment came from C57Bl/6 strain or was genetically 
engineered based on this strain. The mature mice weighed 20-25 g and were 8-10 week old. 
Both gender was used in both group equally.  
The production of Tac1 KO (Zimmer et al. 1998) and NK1 KO (Tacr1 KO)  mice was described 
in details previously (De Felipe et al. 1998; Laird et al. 2000). The original breeding pair of the 
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double knockout strain was generated with the selective crossbreeding of these strains (Tac1 
KO x NK1 receptor KO) and these mice lack the SP/NK1 signal transduction pathway entirely. 
3.1.2 Induction of airway inflammation and experimental setup 
3.1.2.1 Subacute airway inflammation 
The subacute airway inflammation was evoked by intranasal instillation of 60 µl Escherichia 
coli (serotype: 083) endotoxin (167 µg/ml dissolved in sterile PBS) and measurements were 
taken after 24 hours. Control animals received equal volume of sterile PBS. 
3.1.2.2 Chronic airway inflammation 
Chronic airway inflammation was induced by two-month whole body smoke exposure. 
Animals were placed in cages into the smoke exposure chamber and they received smoke 
exposures 10 times a week. Reference cigarette was used for this purpose (Reference 
Cigarette, type 3R4F). 
3.1.3 Measurement of airway reactivity 
Conscious, freely breathing animals were measured by whole body plethysmography. 
Nebulized saline and then muscarin receptor agonist carbachol in increasing concentrations 
(50 µl per mouse in 0, 5.5, 11, 22 mM concentration) was sprayed into the chamber to evoke 
bronchoconstriction after 24 hours of LPS instillation. The so-called “enhanced pause” (Penh) 
was calculated as the indicator of airway resistance. Similar method was followed during the 
measurement of airway inflammation during the smoke exposure experiment. 0, 11, 22 mM 
concentration of carbachol was nebulized into the chambers according to previous 
experiments. Airway reactivity was assessed monthly.  
3.1.4 Bronchoalveolar lavage 
Mice were anaesthetized with ketamine-xylazin and their lungs were washed out with 5 ml of 
cold PBS solution in five portions via a tracheal cannula. The lavage fluids were weighed and 
the cells stained with CD45 FITC and propidium iodide were counted Partec flow cytometer 
device.  
3.1.5 Histopathological analysis and scoring 
The whole right lobe of lung was removed and fixated in 4% formaldehyde for 8 hours, after 
embedding in paraffine, 5-7 µm thick sections were made with microtome and stained with 
hematoxylin-eosin routinely.  Mucus producing goblet cells were visualized with periodic acid 
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Schiff reaction. Sections were evaluated by an  expert pathologist in a blinded fashion (Zeldin 
et al. 2001) semiquantitatively, and composite inflammatory score was calculated.  
3.1.6 Assessment of myeloperoxidase (MPO) activity 
The spectrophotometric MPO assay was performed from the thawed samples on a 96-well 
plate. Briefly, 25 µl assay buffer, 25 µl samples were pipetted in triplicates onto the plate, then 
100 µl  H2O2-3,3′,5,5′-tetramethyl-benzidine (TMB/H2O2) was pipetted into each well. 
Absorbances were read two times: first immediately after the TMB solution was added and 
second time after 5 minutes (kinetic reaction) at 620 nm wavelength on a Multiskan plate 
reader. MPO activity was calculated from the absorbance changes with a calibration curve. 
MPO activites were expressed in unit/mg wet tissue. 
3.1.7 Measurment of inflammatory cytokines in the lung 
Homogenization of lung tissue samples were done in 450 µl RPMI 1640 buffer which contained 
50 µl phenyl-methyl-sulphonyl-fluoride (PMSF). The supernatant of centrifuged homogenates 
was used for the measurement of interleukin 1β (IL-1β) and tumor necrosis faktor-α (TNF-α) 
concentration with specific ELISA technique.  
3.1.8 IL-1β cytokine measurement 
For the measurement of IL-1β cytokine concentration, the thawed tissue samples were 
weighed and homogenized in 0.5 ml RPMI medium containing 1% PMSF on ice for 1 minute.  
Then the homogenates were centrifuged in 4 °C with 10000 g acceleration for 10 minutes and 
the supernatants were used according to the manufacturer’s directions. Results were 
presented in ng/g tissue. 
3.1.9 Statistic 
The percentage Penh values justified to the baseline, the MPO activities and cytokine 
concentrations were expressed as mean ± SEM and evaluated with two-way ANOVA followed 
by Newman-Keuls posttest. The histopathological scores were assessed with Kruskall-Wallis 
test followed by Dunn posttest. Statistical analysis was made with GraphPad Prism 5.02 for 
Windows (GraphPad Software, USA).  Probability values < 0.05 were accepted as significant. 
3.1.10 Ethics 
All experimental procedures were carried out according to the 1998/XXVIII Act of the 
Hungarian Parliament on Animal Protection and Consideration Decree of Scientific Procedures 
of Animal Experiments (243/1988). The studies were approved by the Ethics Committee on 
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Animal Research of University of Pécs according to the Ethical Codex of Animal Experiments 
and licence was given (licence number: BA BA 02/2000-11-2006). 
3.2 Bowel inflammation models 
3.2.1 Animals 
Female Trpv1 gene-deleted (knockout, KO) mice and their C57Bl/6 wild-type counterparts (8–
10 weeks old, 20–25 g) were used for this study. The original breeding pairs of both types were 
purchased from Jackson Laboratories (USA) through Charles-River Hungary.  
In the experiment focusing on NK1 receptors and tachykinins, male NK1 receptor (Tacr1 KO) 
gene-deficient mice were used and backcrossed for 8-10 generations to C57B/6 mice. C57B/6 
mice were used as wild type (WT) controls. NK1 KO mice were generated at the University of 
Liverpool as previously described (Zimmer et al. 1998; De Felipe et al. 1998; Laird et al. 2000; 
Helyes et al. 2004).  
3.2.2 Experimental setup 
3.2.2.1 Induction of colitis 
Colitis was induced with 2% and 5% DSS dissolved in the drinking water and administered for 
7 days. The intact control group of animals received only tap water. Then mice were sacrificed 
in deep ketamine-xylazine anaesthesia (100 mg/kg ketamine i.p.; 5 mg/kg xylazine i.p.) after 
fasting overnight.  The distal colon samples (one third of the colon from anus to cecum) were 
dissected to determine receptor expression, myeloperoxidase enzyme activity, cytokine 
measurement and histopathological evaluation (Szitter et al. 2010).  
3.2.2.2 Netupitant treatment 
The selective synthetic NK1 receptor antagonist netupitant was administered i.p. (6 mg/kg, 
100 µl from the 0.6 mg/ml solution) once a day from the beginning of the experiment for a 
total duration of one week. Mice in the control group of the DSS treatment received the 
vehicle in the same volume according to the same treatment paradigm. A group of receptor 
deficient mice also received the netupitant treatment to identifying any effect caused by 
netupitant beside NK1 receptor blockade. Netupitant stock solution was prepared according 
to the instruction of the manufacturer. Stock solution was stored in 2 °C. This stock solution 
was diluted in saline to prepare the final 0.6 mg/ml solution freshly every day. 
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3.2.3 Receptor expression 
Colon samples were stored in RNAlater and homogenized in 1 ml of TRI Reagent. Isolation of 
total RNA was carried out according to the manufacturer's protocol. The obtained cDNA 
samples were amplified with PCR using specific primers. -actin served as the reference 
housekeeping gene. PCR products were run on agarose gels containing DNA specific dye and 
visualized under UV light. 
3.2.4 Disease Activity Index (DAI) assessment 
The clinical symptoms of colitis, such as body weight change, stool consistency and fecal blood 
content, were scored on a daily basis. Fecal blood content was assessed with Hemocare test 
which uses a modified guaiac method. Scores for the 3 parameters were averaged for each 
mouse to obtain the Disease Activity Index (Kihara et al. 2003). 
3.2.5 Histological evaluation 
The distal colon samples were fixed in 4% buffered formaldehyde, embedded in paraffin, 
sectioned (5 µm), and stained with haematoxylin and eosin. Digital micrographs were taken. 
Inflammatory alterations were evaluated and scored by an expert pathologist blinded from 
the experimental design (Kihara et al. 2003).  Additionally, quantitative assessment was also 
performed to evaluate the histopathological severity of inflammation: the number of inflamed 
foci was counted and percentage of the damaged area was calculated on the digital 
micrographs. 
3.2.6 Myeloperoxidase measurement 
The same method was used as in 3.1.6 section. 
3.2.7 Measurement of IL-1 concentration 
The similar method was applied as described in the 3.1.8 section. 
3.2.8 Cytokine panel assay 
The cytokine assay was performed according to the manufacturer’s instructions. Briefly, the 
excised and frozen tissues were thawed and weighed, and immediately placed in PBS 
containing 10 mg/ml phenyl methyl sulfonyl fluoride (PMSF) protease inhibitor, and 
homogenized as described above. Then Triton X-100 was added to the samples to a final 
concentration of 10 mg/ml and centrifuged at 10000g for 5 minutes to remove cell debris.  
Total protein concentrations were determined prior to cytokine measurement. Chemi-
luminescent detection was performed. The intensity of the emitted light at each spot was 
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proportional to the amount of bound cytokine. Results were calculated by densitometry using 
ImageJ freeware. 
3.2.9 Statistics 
Results are expressed as means ± SEM. For the evaluation of the data, two-way ANOVA (DAI) 
followed by Bonferroni’s post-test; unpaired t-test with Welch correction (MPO activity, 
cytokine profile, quantitative histopathological data) or Mann-Whitney U-test 
(semiquantitative histopathological scores) was used. Statistical analysis was done using 
GraphPad Prism 5.02 for Windows (GraphPad Software, USA). Probability values < 0.05 were 
accepted as significant. 
3.2.10 Ethics 
All experimental procedures were carried out according to the 1998/XXVIII Act of the 
Hungarian Parliament on Animal Protection and Consideration Decree of Scientific Procedures 
of Animal Experiments (243/1988). The studies were approved by the Ethics Committee on 
Animal Research of University of Pécs according to the Ethical Codex of Animal Experiments 
and licence was given (licence number: BA 02/2000-2/2012). 
4. Results 
4.1 Airway inflammation model 
4.1.1 Investigation of the role of tachykinins and NK1 receptors in the endotoxin-
induced acute airway inflammation  
4.1.1.1 Inflammatory airway hyperreactivity in Tac1, NK1 and double knockout mice 
Baseline Penh significantly increased 24 h after intranasal LPS treatment in all groups compared 
to the respective PBS-treated control mice. Inhalation of increasing concentrations (5.5, 11 
and 22 mM) of the muscarinic receptor agonist carbachol evoked a concentration- dependent 
bronchoconstriction. In wild type mice responses demonstrated as percentage increase of Penh 
above baseline were markedly enhanced in the LPS-treated group compared to the respective 
non-inflamed controls which supports the development of inflammatory bronchial hyper-
responsiveness. In Tac1 and Tac1/NK1 gene-deficient mice the LPS-induced airway hyper-
reactivity was markedly reduced, particularly at the highest carbachol concentration. LPS-
evoked airway hyper-reactivity was not significantly decreased in the NK1 receptor-deleted 
group. 
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4.1.1.2 Inflammatory histopathological changes in the lung of Tac1, NK1 and double knockout mice  
LPS induced marked peribronchial/perivascular oedema formation, neutrophil accumulation 
around the bronchi, infiltration of activated recruited macrophages/lymphocytes into the 
alveolar spaces and moderately increased number of mucus producing goblet cells in the wild 
type group. In the lung of PBS-treated control mice there were no inflammatory changes, only 
some macrophages could be observed in the alveolar spaces. Meanwhile, in mice lacking SP 
and NKA due to the deletion of the Tac1 gene, the extent of the oedema and the number of 
the oedematous structures, neutrophil accumulation as well as macrophage infiltration, but 
not goblet cell hyperplasia were significantly less intense, therefore the composite 
inflammation scores calculated from these parameters were also markedly lower. In contrast, 
these inflammatory parameters were not altered by NK1 receptor deletion. Surprisingly, a 
lower oedema intensity and neutrophil accumulation observed in case of missing SP and NKA 
was not seen in mice that did not express the NK1 receptor. We have not observed any 
changes in the control mice in any of the three knockout groups.  
4.1.1.3 Myeloperoxidase activity in the lung homogenates 
LPS induced more than 2-fold elevation of MPO activity in the lung 1 day after intranasal 
administration. This quantitative marker of accumulated neutrophils and macrophages in the 
inflamed tissue was significantly decreased in Tac1 gene-deficient mice, but not in the NK1 
and the Tac1/NK1 knockout animals. 
4.1.1.4 Inflammatory cytokine concentrations in the lung 
Lung IL-1β and TNF-α levels markedly increased 25 h after intranasal LPS administration 
compared to the concentrations measured in the lungs of PBS-treated control animals. The 
absolute concentration of the latter inflammatory cytokine was about 10- fold less. Lung TNF-
α, but not IL-1β concentration was significantly lower in the Tac1 KO group. In contrast, LPS-
induced IL-1β and TNF-α production was elevated in NK1 receptor-deficient animals. No 
change was observed, however, in cytokine concentrations in the pulmonary tissues of the 
double knockout mice 
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4.1.2 The role of the TRPV1, NK1 receptors and Tac1 gene products tachykinins in 
cigarette smoke induced chronic airway inflammation 
4.1.2.1 Airway reactivity 
There is a significant elevation of airway reactivity in the Trpv1 KO mice from the fourth week. 
The NK1 receptor deficient and Tac1 KO animals show increasing tendency only from the 8th 
week but the difference is not significant. 
4.1.2.2 Histopathological changes in chronic airway inflammation 
The appearance of granulocytes and macrophages can be noticed on the slides caused by the 
cigarette smoke evoked chronic inflammation. The inflammatory cell accumulation is more 
prominent in the Trpv1 KO animals especially from the second month. This changes was less 
marked in Tac1 KO mice compared to C57Bl/6 animals while the NK1 KO animals showed more 
marked edema formation and macrophage infiltration compared to the wild type mice. These 
results underline the results of BALF analysis.  
4.1.2.3 Cell count in bronchoalveolar lavage fluid 
The number of granulocytes was elevated in the first month in the C57Bl/6 mice compared to 
the non smoking counterparts and smoking Trpv1 KO animals produced statistically more 
macrophages compared to the smoking wild type animals. At the end of second month, all of 
the inflammatory cell numbers were elevated markedly in the Trpv1 KO animals both in the 
smoking and non-smoking group compared to the wild type mice. The absence of the NK1 
receptors leads to less but significantly elevated cell count compared to the wild type smoking 
groups of animals. 
4.1.2.4 Myeloperoxidase enzyme activity 
All smoking group showed significantly higher myeloperoxidase enzyme activity at the end of 
the first month compared to the intact animals. At the end of second month the MPO enzyme 
activity was significantly higher in the Trpv1 KO and NK1 KO animals compared to the wild 
type smoking animals. 
4.1.2.5 IL-1β cytokine production 
The level of IL-1β cytokine increased in the Trpv1 KO mice after 1 and 2 month of smoking. 
There was no significant changes in the Tac1 KO and NK1 KO animals compared to the wild 
type mice. 
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4.2 Bowel inflammation models: 
4.2.1 The effect of TRPV1 receptors in dextran-sulfate induced murine colitis  
4.2.1.1 Disease Activity Index 
By the end of the seventh day, the clinical symptoms of colitis developed in both the 2% and 
5% DSS-treated groups. Genetic lack of the TRPV1 receptor significantly decreased the DAI in 
the 2% DSS-treated group after day 5. This difference could not be observed in the 5% DSS-
treated group, where severe bloody diarrhea developed both in wild type and knockout 
animals. Five percent DSS produced significantly higher DAI compared to 2% DSS treatment. 
The composite scores were elevated mainly by the increasing blood content of stool. 
4.2.1.2 Semiquantitative histopathological analysis and scoring 
Histopathological scores were evaluated separately for each segment of the colons. 
Composite inflammation scores were higher in all the DSS-treated mice compared to the tap 
water treated control animals in which no signs of inflammation were seen. Treatment with 
5% DSS produced significantly higher tissue damage than the 2% concentration. In the 2% DSS-
treated group, the genetic lack of TRPV1 receptors attenuated the histological changes: there 
was a tendency of milder inflammatory signs; indeed, it was statistically significant in the distal 
segments. In the 5% DSS-treated group, the absence of TRPV1 receptors did not decrease but 
even showed a worsening tendency on the histopathological parameters.  
4.2.1.3 Myeloperoxidase enzyme activity in Trpv1 Ko and wild type mice  
Oral DSS application for 7 days, both in 2% and 5% concentrations, markedly increased MPO 
activity in all the three colon segments compared to the control mice drinking tap water. MPO 
elevation induced by the 2% DSS was significantly higher in all the samples of C57Bl/6 mice 
than in the respective tissues of Trpv1 KO mice. Although 5% DSS treatment caused substantial 
increase of myeloperoxidase content of colon samples compared with the tap water-treated 
controls, there were no significant differences between wild-type and KO animals. 
4.2.1.4 IL-1 production in Trpv1 Ko and wild type animals 
Two percent DSS-induced IL-1β production was only considerable in the distal colon segments; 
the concentrations of this cytokine in the other colon segments were similar to that measured 
in the intact tissues. This moderate, non-significant IL-1β elevation in response to 2% DSS was 
similar in the Trpv1 KO and wild type mice. In contrast, 5% DSS administration caused 
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significant drop in IL-1β levels in both groups; the concentrations were much lower than those 
measured in the homogenates of the intact colons. 
4.2.2 The effect of neurokinin 1 receptor and selective receptor antagonist (netupitant) 
and the tachykinin system in the dextran-sulfate induced colitis model. 
4.2.2.1 Receptor expression 
The receptor expression study revealed that the Tac1 gene (encoding Substance P and NKA) 
was expressed in the distal colon both in the intact control and DSS-treated mice. We could 
not detect the Tac3 and Tac4 genes of NKB and HK-1, respectively. Inflammation did not alter 
this expression pattern. The Tacr1 gene expressing the NK1 tachykinin receptor was 
significantly up-regulated after 7 days of oral DSS administration. There was no expression of 
the Tacr2 and Tacr3 genes of the NK2 and NK3 tachykinin receptors in the intact colon, but 
they were moderately or minimally up-regulated in response to DSS administration. 
4.2.2.2 Disease Activity Index 
DAI was calculated daily on the basis of body weight, stool consistency and fecal blood content 
was significantly reduced from day 6 both by genetic deletion and selective antagonism of the 
NK1 tachykinin receptor with 6 mg/kg i.p. netupitant administration. Netupitant-treated NK1 
receptor-deficient mice showed similar Disease Activity Index compared to vehicle-treated 
receptor-deficient animals. 
4.2.2.3 Histological analysis 
Compared to a histopathological picture of the non-inflamed colon structure showing intact 
crypts and normal mucosal epithelial layer, 2% DSS drinking resulted in a remarkable 
inflammation and tissue damage in the C57Bl/6 wild type group without netupitant treatment. 
There was a significant mucosal and submucosal neutrophil infiltration, loss of the crypts and 
disintegration of the mucosal structure. The severity and the extent of these characteristic 
histopathological alterations were reduced by both NK1 receptor deletion and daily 
administration of the NK1 receptor antagonist netupitant. Meanwhile, in the NK1 KO animals 
netupitant treatment did not influence the severity of inflammation compared to the vehicle-
treated group. These findings were confirmed by the significantly diminished semiquantitative 
score values determined in the NK1 receptor-deficient and netupitant-treated groups in 
comparison with the solvent-treated wild type animals. The quantitative results describing the 
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number of inflamed foci and the percentage values of the damaged areas also showed an anti-
inflammatory effect of netupitant. 
4.2.2.4 Myeloperoxidase enzyme activity 
DSS administration induced an approximately 2-fold increase in MPO activity of the colon 
homogenates compared to the respective intact samples of water-drinking wild type and NK1 
receptor-deficient mice. This elevation was significantly decreased by 6 mg/kg i.p. daily 
netupitant treatment. Surprisingly, netupitant decreased the MPO activity in DSS-treated NK1 
receptor-deficient mice as well compared to their vehicle-treated controls similarly to what 
was observed in wild types.  
4.2.2.5 Murine inflammatory cytokine chip (cytokine array panel) 
Among the 40 investigated cytokines, 11 (BLC, sICAM-1, IFN-γ, IL-1α, IL-1ra, IL-13, IL-16, IP-10, 
JE, MIG, and TIMP-1) were significantly increased in the colon homogenates in response to 
DSS administration in wild type mice compared to their intact controls. In contrast, in the NK1 
receptor-deficient group BLC, sICAM-1, IFN-γ, IL-1α, IL-16, JE did not increase significantly 
while IL-1ra, IP-10, MIG and TIMP were similarly elevated in wild type animals. There was no 
difference between the expressions of these cytokines in the intact colon samples of the two 
groups. Netupitant treatment significantly decreased the DSS-induced elevation of BLC, IFN-
γ, IL-13 and IL-16 levels compared to vehicle administration. These changes were similar to 
the results found in NK1 receptor-deficient mice. 
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5. Summary of new results, conslusions 
1. In the absence of Tac1 encoded tachykinins (SP and NKA) – while not in the absence of 
NK1 receptor – the endotoxin-induced bronchial hyperreactivity, MPO production and 
inflammatory cytokine release are decreased. These peptides are important effectors in 
the acute lung inflammation model but not via the activation of NK1 receptors.  
2. Every inflammatory parameter is aggravated in the smoke-induced airway inflammation 
model in the absence of TRPV1 receptor which means that the activation of this ion 
channel has protective effect. In the lack of SP/NK1 and NK1 receptor increased MPO 
activity was observed which can be explained by the increased macrophage infiltration 
according to the histological analysis and BALF results. In contrast, the IL-1production 
did not change. Surprisingly, in this chronic model (but not in the acute lung inflammation) 
the Tac1 encoded tachykinins inhibit certain inflammatory parameters via the activation 
of NK1 receptors. 
3. The ideal concentration of DSS is 2% in our experiments which with colitis is rendered 
good in mice. Higher concentration such as 5% is proved to be cytotoxic, the tissue 
destruction makes it inappropriate to study the disease. The TRPV1 receptors play 
proinflammatory role in the DSS induced murine colitis ulcerosa model as the developing 
inflammation was less aggravated considering the physiological, histological and 
immunological results. 
4. The expression of Tac1 gene is not upregulated in the DSS induced colitis model but the 
expression of NK1 receptors is increasing. Significantly less inflammatory changes were 
observed on functional, histological and molecular level in case of receptor antagonism 
or receptor deficiency. The NK1 receptor regulates inflammatory processes in the gut in 
a complex manner because the lack of NK1 receptor results in increased MPO activity. 
Results from cytokine panel assay suggest that the activating NK1 receptors increase B-
cell migration, sICAM-1 enhances the adhesion and transmigration of different immune 
cells. The inhibition of NK1 receptors decreases the production of BLC, IFN-γ, IL-13, IL-16 
cytokines therefore they might be promising new targets of further pharmacological 
investigation. 
19 
  
Acknowledgement 
First of all, I would like express my gratitude to my supervisor Zsuzsanna Helyes for the loads 
of help and guidance. I also thank Erika Pintér the leader of the Neuropharmacology PhD 
program to make it possible for me to take part in the research program. She added a lot of 
useful advices to the thesis. Special thank for János Szolcsányi for the concept which created 
a new school. I am thankful for Kata Sándor, Anikó Perkecz, Krisztián Elekes, Teréz Bagoly, 
Ágnes Kemény, Adrienn Markovics and József Kun for the theoretic and practical help during 
the experiments which was indispensable. I am grateful Kata Bölcskei who helped in the 
correction of the manuscript. I thank for the precise assistance of Gyuláné Ömböli, Csilla 
Zádori and Mária Zöldhegyi during my experiments which was essential. I would like to express 
my gratitude for all the members of the Department of Pharmacology and Pharmacotherapy 
who helped in my work in any way. My research work were supported by the Social Renewal 
Operative Program (SROP) subproject numbered 4.2.1.B-10/2/KONV-2010-0002 and 4.2.2.A-
11/1/KONV-2012-0024, I am thankful for this. 
Last, but not least I would like to render thanks for the support, encourage and help of my 
parents. 
  
20 
  
References 
Anavi-Goffer, S. & Coutts, A.A., 2003. Cellular distribution of vanilloid VR1 receptor immunoreactivity 
in the guinea-pig myenteric plexus. European Journal of Pharmacology, 458, pp.61–71. 
Barthó, L. et al., 2004. Effects of capsaicin on visceral smooth muscle: a valuable tool for sensory 
neurotransmitter identification. European Journal of Pharmacology, 500(500), pp.143–157. 
Bhave, G. et al., 2003. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin 
receptor transient receptor potential vanilloid 1 (TRPV1). Proceedings of the National Academy 
of Sciences of the United States of America, 100(21), pp.12480–5. 
Biolow, M. et al., 1990. Cloning and expression of a rat neuromedin K receptor cDNA. The Journal of 
Biological Chemistry, 265(2), pp.623–8. 
Caterina, M.J. et al., 1997. The capsaicin receptor: a heat-activated ion channel in the pain pathway. 
Nature, 389(389), pp.816–824. 
Caterina, M.J. & Julius, D., 2001. The vanilloid receptor: a molecular gateway to the pain pathway. 
Annual Review of Neuroscience, 24(24), pp.487–517. 
Chan, C.L., Facer, P. & Davis, J.B. et al, 2003. Sensory fibres expressing capsaicin receptor TRPV1 in 
patients with rectal hypersensitivity and faecal urgency. Lancet, 361(361), pp.385–391. 
Chu, C.J. et al., 2003. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces 
hyperalgesia. The Journal of Biological Chemistry, 278(16), pp.13633–13639. 
Churg, A., Cosio, M. & Wright, J.L., 2008. Mechanisms of cigarette smoke-induced COPD: insights from 
animal models. American Journal of Physiology - Lung Cellular and Molecular Physiology, 294(4), 
pp.L612–31. 
Clapham, D.E. et al., 2003. Compendium of voltage-gated ion channels: transient receptor potential 
channels. Pharmacological Reviews, 55(55), pp.591–596. 
Cui, M. et al., 2006. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 
antagonists. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 
26(37), pp.9385–93. 
Dai, Y. et al., 2004. Proteinase-activated receptor 2-mediated potentiation of transient receptor 
potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory 
pain. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 24(18), 
pp.4293–9. 
Dedov, V.N. et al., 2002. Gingerols: a novel class of vanilloid receptor (VR1) agonists. British Journal of 
Pharmacology, 137(6), pp.793–798. 
Elekes, K. et al., 2007. Role of capsaicin-sensitive afferents and sensory neuropeptides in endotoxin-
induced airway inflammation and consequent bronchial hyperreactivity in the mouse. Regulatory 
Peptides, 141(1-3), pp.44–54. 
Engel, M.A. et al., 2012. The proximodistal aggravation of colitis depends on substance P released from 
TRPV1-expressing sensory neurons. Journal of Gastroenterology, 47(3), pp.256–65. 
De Felipe, C. et al., 1998. Altered nociception, analgesia and aggression in mice lacking the receptor 
for substance P. Nature, 392(6674), pp.394–397. 
Frossard, N. & Advenier, C., 1991. Tachykinin receptors and the airways. Life Sciences, 49(26), pp.1941–
1953. 
Gaál, C. ed., 2012. Sebészet, Medicina Kiadó. 
Grant, A., 2002. Leukocytes and neurogenic inflammation. Inflammopharmacology, 9, pp.403–420. 
Groneberg, D.A. et al., 2006. Tachykinins in the respiratory tract. Current Drug Targets, 7, pp.1005–
1010. 
Gross, K.J. & Pothoulakis, C., 2007. Role of neuropeptides in inflammatory bowel disease. Inflammatory 
Bowel Diseases, 13(13), pp.918–932. 
Helyes, Zs. et al., 2004. Antiinflammatory and analgesic effects of somatostatin released from 
capsaicin-sensitive sensory nerve terminals in a Freund’s adjuvant-induced chronic arthritis 
model in the rat. Arthritis and Rheumatism, 50(5), pp.1677–85. 
Helyes, Zs. & Hajna, Zs., 2012. Endotoxin-Induced Airway Inflammation and Asthma Models. In A. 
Szallasi & T. Bíró, eds. TRP Channels in Drug Discovery. pp. 301–342. 
21 
  
Holzer, P. & Barthó, L., 1996. Sensory neurons in the intestine. In P. Gepetti & P. Holzer, eds. 
Neurogenic Inflammation. Boca Raton: CRC Press. 
Holzer, P. & Maggi, C., 1998. Dissociation of dorsal root ganglion neurons into afferent and efferent-
like neurons. Neuroscience, 86(86), pp.389–398. 
Huang, S.M. et al., 2002. An endogenous capsaicin-like substance with high potency at recombinant 
and native vanilloid VR1 receptors. Proceedings of the National Academy of Sciences of the United 
States of America, 99(12), pp.8400–5. 
Hwang, S.W. et al., 2000. Direct activation of capsaicin receptors by products of lipoxygenases: 
endogenous capsaicin-like substances. Proceedings of the National Academy of Sciences of the 
United States of America, 97(11), pp.6155–6160. 
Jancsó, N., Jancsó-Gábor, A. & Szolcsányi, J., 1967. Direct evidence for neurogenic inflammation and 
its prevention by denervation and by pretreatment with capsaicin. British Journal of 
Pharmacology and Chemotherapy, 31(31), pp.138–150. 
Jancsó, N., Jancsó-Gábor, A. & Szolcsányi, J., 1968. The role of sensory nerve endings in neurogenic 
inflammation induced in human skin and in the eye and paw of the rat. British Journal of 
Pharmacology and Chemotherapy, 33(33), pp.32–41. 
Kage, R. et al., 1988. Neuropeptide-gamma: a peptide isolated from rabbit intestine that is derived 
from gamma-preprotachykinin. Journal of Neurochemistry, 50(5), pp.1412–7. 
Kihara, N. et al., 2003. Vanilloid receptor-1 containing primary sensory neurones mediate dextran 
sulphate sodium induced colitis in rats. Gut, 52(5), pp.713–719. 
Kimura S., 1983. Novel neuropeptides, neurokinins A and B, isolated from porcine spinal cord. 
Proceedings of the Japan Academy, 5, pp.101–104. 
Konturek, S.J. et al., 1981. Effect of substance P and its C-terminal hexapeptide on gastric and 
pancreatic secretion in the dog. The American Journal of Physiology, 241(1), pp.G74–81. 
Laird, J.M. et al., 2000. Deficits in visceral pain and hyperalgesia of mice with a disruption of the 
tachykinin NK1 receptor gene. Neuroscience, 98(2), pp.345–352. 
Lembeck, F. & Starke, K., 1968. Substance P and salivary secretion. Naunyn-Schmiedebergs Archiv für 
Experimentelle Pathologie und Pharmakologie, 259(5), pp.375–385. 
Liu, L. et al., 2000. Different responses to repeated applications of zingerone in behavioral studies, 
recordings from intact and cultured TG neurons, and from VR1 receptors. Physiology & Behavior, 
69(1-2), pp.177–186. 
Maggi, C., 1995. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released 
from peripheral endings of sensory nerves. Progress in Neurobiology, 45(1), pp.1–98. 
Masu, Y. et al., 1987. cDNA cloning of bovine substance-K receptor through oocyte expression system. 
Nature, 329(6142), pp.836–8. 
Mir Subías, A. et al., 2013. [Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: 
an infrequent but important complication of infliximab in Crohn’s disease]. Gastroenterología y 
Hepatología, 36(2), pp.81–5. 
Nawa, H. et al., 1984. Substance K: a novel mammalian tachykinin that differs from substance P in its 
pharmacological profile. Life Sciences, 34(12), pp.1153–60. 
Page, N.M., 2006. Characterization of the gene structures, precursor processing and pharmacology of 
the endokinin peptides. Vascular Pharmacology, 45(4), pp.200–208. 
Page, N.M., 2004. Hemokinins and endokinins. Cellular and Molecular Life Sciences, 61(13), pp.1652–
63. 
Page, N.M., 2005. New challenges in the study of the mammalian tachykinins. Peptides, 26(8), 
pp.1356–1368. 
Patacchini, R., Maggi, C. & Meli, A., 1990. Capsaicin-like activity of some natural pungent substances 
on peripheral endings of visceral primary afferents. Naunyn-Schmiedeberg’s Archives of 
Pharmacology, 342(1), pp.72–77. 
Patterson, L.M. et al., 2003. Vanilloid receptor (VR1) expression in vagal afferent neurons innervating 
the gastrointestinal tract. Cell and Tissue Research, 311(311), pp.277–287. 
22 
  
De Petrocellis, L. et al., 2001. The vanilloid receptor (VR1)-mediated effects of anandamide are potently 
enhanced by the cAMP-dependent protein kinase. Journal of Neurochemistry, 77(6), pp.1660–3. 
Pintér, E. & Szolcsányi, J., 1996. Systemic anti-inflammatory effect induced by antidromic stimulation 
of the dorsal roots in the rat. Neuroscience Letters, 212, pp.33–36. 
Piusińska-Macoch, R., 2013. [Neurological complications during treatment of the tumor necrosis alpha 
inhibitors]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 34(203), 
pp.293–7. 
Poonyachoti, S., Kulkarni-Narla, A. & Brown, D.R., 2002. Chemical coding of neurons expressing delta- 
and kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum. 
Cell and Tissue Research, 307(307), pp.23–33. 
Premkumar, L.S. et al., 2004. Enhancement of potency and efficacy of NADA by PKC-mediated 
phosphorylation of vanilloid receptor. Journal of Neurophysiology, 91(3), pp.1442–9. 
Rathee, P.K. et al., 2002. PKA/AKAP/VR-1 module: A common link of Gs-mediated signaling to thermal 
hyperalgesia. The Journal of neuroscience : the official journal of the Society for Neuroscience, 
22(11), pp.4740–5. 
Regoli, D., Boudon, A. & Fauchére, J.L., 1994. Receptors and antagonists for substance P and related 
peptides. Pharmacological Reviews, 46(4), pp.551–599. 
Shapiro, S.D., 2000. Animal models for COPD. Chest, 117(5 Suppl 1), p.223S–7S. 
Stewart, J.P.J. et al., 2008. Induction of tachykinin production in airway epithelia in response to viral 
infection. PloS one, 3(3), p.e1673. 
De Swert, K.O. & Joos, G.F., 2006. Extending the understanding of sensory neuropeptides. European 
Journal of Pharmacology, 533(1-3), pp.171–181. 
Szallasi, A. & Blumberg, P.M., 1989. Neurogenic component of phorbol ester-induced mouse skin 
inflammation. Cancer Research, 49(21), pp.6052–6057. 
Szallasi, A. & Blumberg, P.M., 1990. Resiniferatoxin and its analogs provide novel insights into the 
pharmacology of the vanilloid (capsaicin) receptor. Life Sciences, 7, pp.1399–1408. 
Szitter, I. et al., 2010. The role of transient receptor potential vanilloid 1 (TRPV1) receptors in dextran 
sulfate-induced colitis in mice. Journal of Molecular Neuroscience, 42(1), pp.80–8. 
Szolcsányi, J., 1984. Capsaicin-sensitive chemoceptive neural system with dual sensory-efferent 
function. In L. A. Chahl, J. Szolcsanyi, & F. Lembeck, eds. Antidromic Vasodilatation and 
Neurogenic Inflammation. Budapest: Akadémiai Kiadó, pp. 27–55. 
Szolcsányi, J., 1996. Capsaicin-sensitive sensory nerve terminals with local and systemic efferent 
functions: facts and scopes of an unorthodox neuroregulatory mechanism. Progress in Brain 
Research, 113, pp.343–359. 
Szolcsányi, J., Helyes, Z., et al., 1998. Release of somatostatin and its role in the mediation of the anti-
inflammatory effect induced by antidromic stimulation of sensory fibres of rat sciatic nerve. 
British Journal of Pharmacology, 125, pp.936–942. 
Szolcsányi, J., Pintér, E., et al., 1998. Systemic anti-inflammatory effect induced by counter-irritation 
through a local release of somatostatin from nociceptors. British Journal of Pharmacology, 125, 
pp.916–922. 
Szolcsányi, J., 1983. Tetrodotoxin-resistant non-cholinergic neurogenic contraction evoked by 
capsaicinoids and piperine on guinea-pig trachea. Neuroscience Letters, 42, pp.83–88. 
Tatemoto, K. et al., 1985. Neuropeptide K: isolation, structure and biological activities of a novel brain 
tachykinin. Biochemical and Biophysical Research Communications, 128(2), pp.947–53. 
Tominaga, M. et al., 1998. The cloned capsaicin receptor integrates multiple pain-producing stimuli. 
Neuron, 21(3), pp.531–543. 
Trevisani, M. et al., 2002. Ethanol elicits and potentiates nociceptor responses via the vanilloid 
receptor-1. Nature Neuroscience, 5(6), pp.546–551. 
Ward, S.M. et al., 2003. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. Journal 
of Comparative Neurology, 465, pp.121–135. 
Wood, J.N. et al., 1988. Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture. The Journal 
of Neuroscience : the official journal of the Society for Neuroscience, 8(9), pp.3208–20. 
23 
  
Yamamoto, H. et al., 1996. Abnormal neuropeptide concentration in rectal mucosa of patients with 
inflammatory bowel disease. Journal of Gastroenterology, 31(4), pp.525–532. 
Yokota, Y. et al., 1989. Molecular Characterization of a Functional cDNA for Rat Substance P Receptor. 
The Journal of Biological Chemistry, 264(30), pp.17649–17652. 
Zeldin, D.C. et al., 2001. Airway inflammation and responsiveness in prostaglandin H synthase-deficient 
mice exposed to bacterial lipopolysaccharide. American Journal of Respiratory Cellular and 
Molecular Biology, 25(4), pp.457–465. 
Zhang, Y. et al., 2000. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. 
Nature Immunology, 1(5), pp.392–7. 
Zimmer, A.M. et al., 1998. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. 
Proceedings of the National Academy of Sciences of the United States of America, 95(5), pp.2630–
2635. 
 
  
24 
  
List of publications 
Full-length articles related to the present thesis 
Szitter I, Pintér E, Perkecz A, Kemény Á, Kun J, Pietra C, Quinn J P, Zimmer A, Berger A, Paige 
C J, Helyes Zs „Role of neurokinin 1 receptors in dextran sulfate-induced colitis: studies 
with gene-deleted mice and the selective receptor antagonist netupitant”. Inflammation 
Research (2014) (IF: 2,143 (2013)) 
Szitter I, Pozsgai G, Sándor K, Elekes K, Kemény Á, Perkecz A, Szolcsányi J, Helyes Zs, Pintér E 
“The role of transient receptor potential vanilloid 1 (Trpv1) receptors in dextran sulfate-
induced colitis in mice”. Journal Of Molecular Neuroscience 42:(1) pp. 80-88. (2010) (IF: 
2,922, FC: 12) 
Helyes Zs, Elekes K, Sándor K, Szitter I, Kereskai L, Pintér E, Kemény A, Szolcsányi J, McLaughlin 
L, Vasiliou S, Kipar A, Zimmer A, Hunt S P, Stewart J P, Quinn J P “Involvement of 
preprotachykinin A gene-encoded peptides and the neurokinin 1 receptor in endotoxin-
induced murine airway inflammation”.  Neuropeptides 44:(5) pp. 399-406. (2010) (IF: 
1,917 FC: 7) 
Cumulative impact factor of the articles related to the present thesis: 6,982 
Number of independent citations: 19 
Conference presentations related to the present thesis 
Szitter I, Pintér E, Perkecz A, Kemény Á, Pietra C, Quinn J P, Zimmer A, Berger A, Helyes Zs „Effect of 
neurokinin 1 (NK1) receptor antagonism and the differential role of NK1 receptors in dextran-
sulfate (DSS) induced colitis in mice” In: Proceedings of the British Pharmacological Society. Place 
and date of conference: Granada, Spain, 2012.07.17-2012.07.20. Paper C049 (2012) (poster) 
Szitter I, Pintér E, Kemény Á, Pietra C, Quinn J, Zimmer A, Berger A, Helyes Zs “Neurokinin 1 (NK1) 
receptor antagonizmus hatása és a NK1 receptorok szerepe a dextrán-szulfáttal (DSS) kiváltott 
colitisben egérmodellben” p. 189. A Magyar Élettani Társaság a Magyar Anatómusok Társasága a 
Magyar Biofizikai Társaság és a Magyar Mikrocirkulációs és Vaszkuláris Biológiai Társaság 
Kongresszusa abstract booklet, Debrecen, Hungary, 2012.06.10-2012.06.13 (2012) (poster) 
Szitter I, Pintér E, Perkecz A, Berger J A, Paige C J, Szolcsányi J, Helyes Zs „Role of the tachykinin system 
in dextran sulphate-induced colitis in mice” In: Journal of Molecular Neuroscience. Place and date 
of conference: Boston, USA, 2011.05.22-2011.05.25. p. 199. (2011) (poster) 
Szitter I, Pintér E, Pozsgai G, Sándor K, Kemény Á, Perkecz A, Elekes K, Helyes Zs, Szolcsányi J, Quinn J 
“Investigation of the role of TRPV1 capsaicin receptors and tachykinins in dextrane-sulphate 
induced mouse colitis model” Tue 271. 16th World Congress on Basic and Clinical Pharmacology 
(WorldPharma2010), Copenhagen, Denmark 2010.07.17-2010.07.23. (2010) (poster) 
Szitter I, Pintér E, Sándor K, Bánvölgyi A, Elekes K, Szolcsányi J, Quinn J, Helyes Zs “Investigation of the 
role of TRPV1 capsaicin receptors and tachykinins in dextrane-sulphate induced mouse colitis 
model” Acta Physiologica Hungarica 97:(1) pp. 139-140. (2010) (IF: 1,226) (poster) 
25 
  
Szitter I, Pintér E, Markovics A, Perkecz A, John Q, Szolcsányi J, Helyes Zs „Tachykininek szerepének 
vizsgálata génhiányos egerekkel dextrán-szulfáttal kiváltott bélgyulladás modellben” In: A Magyar 
Élettani Társaság (MÉT) LXXIV. Vándorgyűlése és a Magyar Kísérletes és Klinikai Farmakológiai 
Társaság (MFT) II. Közös Tudományos Konferenciája. Place and date of conference: Szeged, 
Hungary, 2010.06.16-2010.06.18. Szeged: Szegedi Tudományegyetem, Paper P139. (2010) 
(poster) 
Szitter I, Pintér E, Sándor K, Bánvölgyi Á, Elekes K, Szolcsányi J, John Q, Helyes Zs “A TRPV1 kapszaicin 
receptor és a tachykininek szerepének vizsgálata dextrán-szulfáttal kiváltott bélgyulladás 
modellben” p. 51. Biológus Doktoranduszok Konferenciája, Pécs, Hungary, 2009.11.12-
2009.11.13. (2009) (oral presentation) 
Pintér E, Szitter I, Sándor K, Bánvölgyi A, Elekes K, Szolcsányi J, Quinn J P, Helyes Zs “Investigation of 
the role of TRPV1 capsaicin receptors and tachykinins in dextran sulfate- induced mouse colitis 
model” Neuropeptides 43:(5) pp. 427-428. (2009) (IF: 2,036) (poster) 
Articles not related to the thesis 
Sütő B, Szitter I, Bagoly T, Pintér E, Szolcsányi J, Loibl Cs, Námeth T, Tánczos K, Molnár T, Leiner T, 
Várnai B, Bardonicsek Zs, Helyes Zs “Plasma somatostatin-like immunoreactivity increases in the 
plasma of septic patients and rats with systemic inflammatory reaction: experimental evidence 
for its sensory origin and protective role”. Peptides 54: pp. 49-57. (2014) (IF: 2,614 (2013)) 
Other conference and poster presentations 
Szitter I, Kiss T, Perkecz A, Helyes Zs „Lung morphometry: quantitative assessment of tissue changes 
in mice exposed to chronic whole body cigaretta smoke” In: Bruker User Meeting 2013. Place and 
date of conference: Hasselt, Belgium, 2013.04.16-2013.04.18. pp. 93-95. (2013) (oral 
presentation) 
Kun J, Helyes Zs, Szitter I, Gódi Sz, Szabó I, Kemény Á, Pohóczky K, Perkecz A, Pintér E “A tranziens 
receptor potenciál ankyrin 1 (TRPA1) és vanilloid 1 (TRPV1) receptor mRNS expresszió gyulladásos 
bélbetegségben (IBD) és dextrán-szulfát (DSS) által indukált egér colitis modellben” p. A-0184. A 
Magyar Élettani, Farmakológiai és Mikrocirkulációs Társaságok 2013. évi közös Tudományos 
Kongresszusa, Budapest, Hungary, 2013.06.05-2013.06.08. (2013) (poster) 
Szitter I, Barbara K, Kiss T, Perkecz A, Feller D, Helyes Zs “Tüdő morfometria: dohányfüst okozta szöveti 
elváltozások kvantitatív követése mikroCT módszerrel C57Bl/6 és galanin 3 receptor (Gal3r) 
deficiens egerekben” p. A-0191.A Magyar Élettani, Farmakológiai és Mikrocirkulációs Társaságok 
2013. évi közös Tudományos Kongresszusa, Budapest, Hungary, 2013.06.05-2013.06.08. (2013) 
(poster) 
Kemény Á, Boros M, Hajna Zs, Szitter I, Sétáló Gy, Szolcsányi J, Pintér E, Helyes Zs “Complex cytokine 
profiling of tissues obtained from chronic mouse inflammation models” p. P300. 6th European 
Congress of Pharmacology (EPHAR2012), Granada, Spain, 2012.07.17-2012.07.20. (2012) (poster) 
  
26 
  
Helyes Zs, Szitter I, Hajna Zs, Elekes K, Kemény Á, Kereskai L, Quinn J P, Sándor K, Pintér E, Szolcsányi J 
“Role of the TRPV1 ion channel and sensory neuropeptides in cigarette smoke-induced chronic 
airway inflammation model of the mouse” BPS Focused Meeting on Neuropeptides, London, 
Anglia, 2012.06.07-2012.06.09. (2012) (oral presentation) 
Kun J, Pintér E, Szitter I, Szabó I, Gódi Sz, Perkecz A, Helyes Zs “A tranziens receptor potenciál ankyrin 
1 (TRPA1) receptor expresszióváltozása gyulladásos bélbetegségben (IBD) és dextrán-szulfát által 
indukált egér colitis modellben” p. 135. A Magyar Élettani Társaság a Magyar Anatómusok 
Társasága a Magyar Biofizikai Társaság és a Magyar Mikrocirkulációs és Vaszkuláris Biológiai 
Társaság Kongresszusa abstract booklet, Debrecen, Hungary, 2012.06.10-2012.06.13. (2012) 
(poster) 
Kun J, Pintér E, Gódi S, Szabó I, Szitter I, Perkecz A, Helyes Zs “Expression change of the transient 
receptor potential ankyrin 1 (TRPA1) receptor in inflammatory bowel disease (IBD) and dextran 
sulfate-induced colitis in mice” p. P302. Proceedings of the British Pharmacological Society, 
Granada, Spain, 2012.07.17-2012.07.20. (2012) (poster) 
Elekes K, Sándor K, Szőke E, Tóth D, Markovics A, Szitter I, Jakab L, Szakacs B, Kereskai L, Szolcsányi J, 
Molnár T, Helyes Zs “Peripheral effect of the marijuana smoke in the lung of mice” Mon 283. 16th 
World Congress on Basic and Clinical Pharmacology (WorldPharma2010), Copenhagen, Denmark, 
2010.07.17-2010.07.23. (2010) (poster) 
Cumulative impact factors of all publications: 12,858 
Number of all the independent citations: 19 
 
 
